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Human cutaneous dendritic cells (DCs) from epidermal and dermal compartments exhibit functional
differences in their induction of CD4þ T-cell and humoral immune responses; however, differences in the
regulation of memory CD8þ T-cell responses by human skin DCs remain poorly characterized. We tested the
capacity of human Langerhans cells (LCs) and dermal dendritic cells (DDCs) to induce antigen-specific cytokine
production and proliferation of memory CD8þ cells. Although tumor necrosis factor-a-matured human DCs
from both epidermal and dermal compartments showed efficient potential to activate CD8þ cells, LCs were
constitutively more efficient than DDCs in cross-presenting CD8þ epitopes, as well as direct presentation of
viral antigen to Epstein–Barr virus-specific CD8þ T cells. LCs showed greater expression of CD70, and blockade
of CD70–CD27 signaling demonstrated that superiority of CD8þ activation by epidermal LC is CD70 dependent.
This CD70-related activation of CD8þ cells by LCs denotes a central role of LCs in CD8þ immunity in skin, and
suggests that regulation of LC CD70 expression is important in enhancing immunity against cutaneous epithelial
pathogens and cancer.
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INTRODUCTION
Dendritic cells (DCs) orchestrate the immune response in the
peripheral tissues by sensing the microenvironment to aid
recognition of potentially dangerous pathogens, initiating
either immunity or tolerance depending upon these signals
(Banchereau and Steinman, 1998). In skin, Langerhans cells
(LCs) in the epidermis use their dendrites to reorganize upper
epidermal tight junctions, allowing constant sampling of the
tissue and environment and, through their location, are
exposed early to infections and skin cancer (Kubo et al.,
2009). Although LCs have long been known to act as key
sentinels to human immunity, more recently dermal popula-
tions of DCs (dermal dendritic cells, DDCs) have been
identified (Lenz et al., 1993; Nestle et al., 1993). Investigation
of the relative activities of these DCs in humans from these
distinct anatomical compartments has been hampered by
difficulties in obtaining large numbers of fresh cells from the
skin (Cunningham et al., 2008; Fahey et al., 2009), and
consequently surprisingly little is known about their function
in vivo (Nestle et al., 2009).
Both LCs and DDCs have been shown to be able to take
up cutaneous antigens, mature and migrate to draining local
lymph nodes, and to present antigens to T and B cells
(Schuler and Steinman, 1985; Romani et al., 1989; Dubois
et al., 1998; Nestle et al., 1998; Kissenpfennig et al., 2005).
LCs and DDCs use matrix metalloproteinases 9 and 2 to
migrate out toward the lymph node; however, LCs also need
to exit the epidermis by migrating through basement
membrane pores (Ratzinger et al., 2002; Oakford et al.,
2011). Furthermore, human LCs have been shown to more
efficiently prime naive CD4þ cells than dermal CD14 DCs
and are better able to induce proliferation in naive CD8þ
cells in a mixed-lymphocyte reaction (Klechevsky et al.,
2008; Furio et al., 2010). Despite this, the role of the LCs has
been called into question because of experimental murine
models demonstrating their apparent redundancy in the
cutaneous immune response (Zhao et al., 2003; Ritter et al.,
2004; Bennett et al., 2005; Kaplan et al., 2005; Noordegraaf
et al., 2010). The differences in the methodology used for
ablating or deleting LCs and the variable results in
these publications have meant that this concept has not met
universal acceptance (Zaba et al., 2009). In other systems,
DC subtypes have been found to induce different T helper
cell functional outcomes in mice (Crowley et al., 1989;
Pulendran et al., 1997; Reis e Sousa et al., 1997) and humans
(Rissoan et al., 1999); thus, functional studies in mice may
not clarify the role of the various DCs in humans. Indeed, it
seems likely that sensitive immunosurveillance of the
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epidermis is critical not only because of the exposure of this
skin layer to exogenous infectious pathogens, but also
because nearly all skin cancers (including basal cell
carcinoma, squamous cell carcinoma, and malignant mela-
noma) initiate within this compartment. In addition, UV
irradiation induces an immunosuppressive LC phenotype
(Schwarz et al., 2010), and chronic UVR in humans is
associated with the induction of skin cancer. Furthermore,
activation of LCs with an epidermally applied Toll-like
receptor (TLR7) agonist (imiquimod; Burns et al., 2000;
Suzuki et al., 2000) is used clinically in the treatment of both
cutaneous virus infections (human papilloma virus) and some
skin cancers (Edwards et al., 1998; Powell et al., 2009).
Therefore, although LC function has yet to be fully
characterized, these observations raise the question as to
whether LCs have a role in host immunity against viral and
neoplastic hazards within the epidermis.
To further clarify LC and DDC function, in our study, we
examined the ability of these distinct cell populations to
activate CD8þ T lymphocytes. Using DCs isolated directly
from human skin, we demonstrate that mature epidermal LCs
are significantly better able than DDCs to activate CD8þ
T cells. Moreover, LCs express higher levels of the CD70
transmembrane glycoprotein than their dermal counterparts,
and signaling via CD70–CD27 pathway is responsible for the
superior stimulation of human memory CD8þ T cells by LCs.
RESULTS
Freshly harvested migratory skin DCs are functional and are
able to stimulate antigen-specific CD8þ T-cell responses
After separation of the epidermis and dermis, two fully
functional populations of human skin DCs were isolated by
migration and purified by density gradient centrifugation.
Epidermal and dermal populations contained a similar
frequency of HLA-DR-expressing cells, confirming an equiva-
lent fraction of DCs (Figure 1a, data representative for
n¼3–6). Epidermal DCs expressed CD1a at high levels, and
were CD11c negative and CD207 positive, consistent with LC
phenotype. The dermal migratory population of DCs com-
prised predominantly CD1alow and CD1aintermediate CD11c-
positive cells characteristic of DDCs. Further analysis showed
that this population is heterogeneous with respect to expres-
sion of CD14, as described previously (Angel et al., 2006).
Only 1.3% of all DDCs expressed high CD1a and CD207,
consistent with a langerin-expressing DDC phenotype.
To investigate how cutaneous DCs from different skin
compartments regulate CD8þ T-cell function, we examined
the potential of skin DCs to induce CD8þ T-cell activation
as reflected by cytokine production and proliferation. First,
we used the 9-amino-acid HLA-A2-restricted Epstein–Barr
virus (EBV) BMLF-1 protein epitope (EBV peptide; Black
et al., 2006) to generate a highly enriched HLA-A2 EBV
peptide–specific CD8þ T-cell line (Supplementary Figure
S1a–c online). Following peptide pulsing with EBV-peptide
HLA-A2, LCs or DDCs (from 12 skin donors) were used to
stimulate EBV peptide–restricted T cells. Efficiency of antigen
presentation was assayed by measurement of IFN-g secretion
by ELISpot. Skin DCs from both the epidermal and dermal
compartment showed a similar potential to induce CD8þ
T-cell activation (Figure 1b).
Mature LCs show functional superiority over DDCs in antigen-
specific CD8þ T-cell activation
To examine further whether skin DCs possess the same
efficiency of CD8þ T-cell activation, we tested their function
after maturation signals. Therefore, the capacity of EBV
peptide–pulsed tumor necrosis factor (TNF)-a-matured human
skin–derived DCs to activate EBV-specific CD8þ T cells in
an HLA-restricted manner was assessed. T-cell cytokine
generation by flow cytometric analysis of intracellular
staining for TNF-a and IFN-g in live CD3þ cells was
performed (n¼5), as well as ELISpot assay for IFN-g secretion
(n¼12) and 3[H]-thymidine incorporation assay for T-cell
proliferation (n¼6) were carried out. Peptide presentation by
skin DCs induced the T-cell lines to produce predominantly
IFN-g (Figure 2a), which is important in antiviral responses.
Notably, the IFN-g response of CD8þ lymphocytes stimu-
lated by LCs was significantly greater (P¼0.0008, 12
independent experiments in triplicate) than when EBV-
specific T cells were stimulated by DDCs (Figure 2b).
Similarly, LCs induced significantly greater proliferation
(P¼0.008) of antigen-specific T lymphocytes than that
following T-cell culture with DDCs (Figure 2c).
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Figure 1. Freshly harvested migratory skin dendritic cells are functional and
able to stimulate antigen-specific CD8þ T-cell responses. (a) Epidermal and
dermal skin migratory cells were phenotyped using antibodies to HLA-DR,
CD1a, CD11c, CD14, and CD207 to identify the dendritic cell populations
(data representative for n¼3–6). Epidermal migratory cells were CD1ahigh,
CD11cneg, CD14neg cells, whereas the dermal populations were CD11cpos,
CD1alow/intermediate, and contained a low fraction of CD14-expressing cells.
Frequency of CD207 expression was high in epidermal but not in dermal
migratory cells. Values represent % of total gated population. Both epidermal
and dermal migratory cell populations contain similar numbers of dendritic
cells. (b) Activation of EBV-specific T cells by freshly harvested HLA-matched
EBV peptide–pulsed (EBV) LCs (white) and DDCs (gray) or unpulsed (control;
stippled) as measured by IFN-g ELISpot, n¼5 independent experiments in
triplicate (mean±SEM). DDC, dermal dendritic cell; EBV, Epstein–Barr virus;
LC, Langerhans cell.
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LC upregulates CD70
Following the identification of the functional superiority of
LCs to activate CD8þ T cells, we set out to explore whether
this difference was associated with surface co-stimulatory
molecule expression. We examined the expression of
antigen-presenting and co-stimulatory molecules on freshly
harvested and in vitro TNF-a-matured migratory cutaneous
DCs from 12 donors. HLA class II expression was equal
in both epidermal (CD1ahigh) and dermal (CD1alow) DC
populations, and both exhibited similarly low levels of CD83
expression, which increased following in vitro maturation
(Figure 3a). HLA class I, CD40, and CD86 expression were
higher in LCs than in DDCs, suggesting a more activated
status of epidermal DCs; however, upon in vitro maturation
with TNF-a, the differences in HLA class I and CD40 between
these cell types were reduced. However, the most striking
distinction between the DC populations from the two skin
compartments was the upregulation of the expression of
CD70 in TNF-a-matured LCs (Po0.01, Figure 3a and b;
Supplementary Figure S2 online). To further explore the
regulation of CD70 expression on subpopulations of DDCs,
we analyzed CD70 expression on TNF-a-matured CD14þ ,
CD1alow, CD1aintermediate, and CD1ahigh expressing DDC
populations (n¼ 3). Each of the DDC subpopulations
expressed low levels of CD70, except for CD1ahigh DDCs
(accounting for B1.3% of the total DDC population) that
showed similar CD70 expression to TNF-a-matured LCs. This
is consistent with the previous reports, suggesting that
CD1ahigh DDCs represent in transit LCs (Larsen et al., 1990).
Cytokine production by TNF-a-matured skin DCs
To assess whether the differences in activation of EBV-
specific T lymphocytes could be because of the release of
cytokines by activated DCs, we tested an array of cytokines
relevant to lymphocyte polarization and proliferation, in-
cluding IL-1b, IL-4, IL-6, IL-8, IL-10, IL-12p70, TNF-a, IL-15,
and IL-27 (Figure 3d; n¼ 3, independent experiments, in
duplicate). In accordance with previous reports (Berthier-
Vergnes et al., 2005), LCs produced only low levels of IL-
12p70, which was not significantly different from DDCs
(P¼0.13), whereas DDCs produced higher levels of IL-6
(P¼0.003) and IL-8 (P¼0.04); however, no significant
differences between DC populations were identified for
expression of TNF-a, IL-1b, IL-4, IL-10, and IL-27. In
accordance with previous publications, only low levels of
IL-15 were detected (Ratzinger et al., 2004; Munz et al.,
2005; Santegoets et al., 2008; Furio et al., 2010).
Blockade of CD70 signaling abrogates the superiority of LCs to
activate CD8þ T cells
There is strong evidence that differences exist in the use of the
CD70–CD27 co-stimulatory pathway among DC subsets
(Belz et al., 2007a, 2007b; Ballesteros-Tato et al., 2010),
and recent work has shown that in a model of influenza
infection only a specific subpopulation of lung DCs were able
to upregulate CD70 expression, which was critical for the
expansion of influenza-specific CD8þ T-cell populations
(Ballesteros-Tato et al., 2010). To determine whether the
higher levels of CD70 expression seen in LCs could account
for the higher capacity of these cells to activate CD8þ T
cells, we first confirmed high levels of expression of CD27,
which is the cognate ligand to CD70, on the HLA-matched
EBV-specific memory T-cell population (Figure 4a). To
explore the effect of neutralizing CD70 on skin DC–CD8
activation, we tested a dose–response of anti-CD70-neutraliz-
ing mAb (Abcam, UK) and confirmed that relatively low
concentrations were able to inhibit LC function but not DDC
function (Figure 4b). To test the role of CD70–CD27
interaction in the superiority of LC activation of CD8þ cells,
the effect of neutralizing CD70 (n¼3) on the ability of
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Figure 2. Langerhans cells show functional superiority over dermal dendritic
cells in antigen-specific CD8þ T-cell activation. (a) IFN-g and TNF-a
intracellular cytokine staining of CD3þCD4þ (left panels) and
CD3þCD8þ (right panels) viable EBV-specific T lymphocytes following
activation by TNF-a-matured EBV peptide–pulsed LCs (upper) or DDCs
(lower). Values in quadrants represent % of total gated population.
Data are representative of n¼5. (b) Activation of EBV-specific T cells by
TNF-a-matured EBV peptide–pulsed LCs (white) and DDCs (gray) as measured
by IFN-g ELISpot. Background deducted, n¼12 independent experiments in
triplicate. (c) Short-term 3[H]-TdR proliferation assay comparing
TNF-a-matured EBV-pulsed LC or DDC induction of proliferation of
EBV-specific CD8þ lymphocytes at 1:50 stimulator/responder ratio.
Stimulation index (SI)¼ T cells (A2 pulsed LC or DDC) c.p.m./T cells
alone c.p.m. DDC, dermal dendritic cell; EBV, Epstein–Barr virus; LC,
Langerhans cell; SFU, spot forming units; TNF-a, tumor necrosis factor-a.
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TNF-a-matured skin DCs to expand an EBV-specific CD8þ
T-cell line was examined. Blockade of CD70 in LC/T-cell
cultures caused an almost complete abrogation in expansion of
antigen-specific T cells (P¼ 0.03, Figure 4c). By contrast, anti-
CD70 did not modify DDC expansion of EBV-specific T cells.
The superiority of LC induction of CD8 expansion was further
confirmed with 3[H]-thymidine incorporation assays (Figure
4d). The higher proliferation of CD8þ T cells following
stimulation by LCs was significantly reduced with CD70
blockade (P¼ 0.015), whereas addition of anti-CD70 antibo-
dies to DDC/T-cell cultures did not alter T-cell proliferation.
The role of skin DC CD70–CD27 ligation for effector T-cell
activation was assessed by ELISpot assay of IFN-g production
following overnight co-culture of DC with EBV-specific CD8
cells. Addition of anti-CD70 antibody resulted in a significant
reduction in the activation of CD8þ T cells by LCs but did
not inhibit activation by DDCs (LCs 20.1%±12.4, P¼0.02;
DDCs 0.00%±20.9; P¼ 0.98, n¼10; Figure 5). Further-
more, neutralization of CD70 reduced LC activation
of CD8þ T cells to levels that were no different from
DDC-induced CD8þ activation (P¼ 0.83). As might
be expected, antibody-mediated blockade of CD86 reduced
activation of CD8þ T cells by both subtypes of skin DCs
(LCs 31.1%±12.6, P¼0.01; DDCs 14.7%±18.8, P¼0.08;
Figure 5, n¼ 10); however, DDCs were still capable
of activating CD8þ T cells, suggesting that DDCs may
also express other co-stimulatory molecules (Duttagupta
et al., 2009).
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Figure 3. Maturation induced upregulation of CD70 in Langerhans cells but not in dermal dendritic cells. (a) Flow cytometric histogram analysis of surface
expression of markers of maturation and activation on migratory LCs from the epidermis (CD1a/HLA-DRhigh; black) and DDCs (CD11c/HLA-DRhigh; gray) before
(left panel) and after (right panel) maturation with TNF-a. The data are representative of 12 independent skin specimens. (b) CD70 expression in LCs (open bar),
TNF-a-matured LCs (striped bar), DDCs (gray bar), and matured DDCs (gray striped bar) as determined by mean fluorescence intensity of flow cytometric
analysis of CD70 expression (n¼12). (c) Flow cytometric histogram analysis of surface expression of CD70 expression on matured migratory LCs from the
epidermis (CD1a/HLA-DRhigh; gray) and dermal migratory dendritic cells (HLA-DRhigh; black); whole migratory dermal population (DDC), CD14þ (CD14), and
CD14– (CD1alow; CD1aintermediate; CD1ahigh) (n¼ 3). (d) Expression of cytokines by LCs (white bars) and DDCs (dark bars) cultured with TNF-a for 24 hours was
assayed using Luminex assay (IL-1b, IL-4, IL-6, IL-8, IL-10, TNFa) and by ELISA (IL-12p70, IL-15, IL-27). #, Below detection threshold of assay. Mean±SEM of
three independent experiments in duplicate. DDC, dermal dendritic cell; LC, Langerhans cell; NS, nonsignificant; TNF-a, tumor necrosis factor.
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LCs are more efficient in cross-presentation to CD8þ T cells
than DDCs and use CD70 co-stimulation
To test the potential for DC subset cross-presentation,
previous studies have used long peptides that cannot be
directly loaded into surface major histocompatibility com-
plex (MHC) class I molecules (Klechevsky et al., 2008).
Furthermore, such long peptides have also been found to
induce robust T-cell immune responses for use as vaccines,
and they have the added advantage of directly targeting
professional antigen-presenting cells for initiation of immu-
nity because the functionality of cross-presentation is relatively
restricted to these cell types (Melief and van der Burg, 2008).
Therefore, to investigate whether the superiority of LC in
activation of peptide-specific CD8þ T cells is sustained when
the antigen is taken up from an extracellular source, we used
a long 39-amino-acid peptide (proGLC) containing the EBV
BMLF-1 epitope, which would be expected to require
endocytosis by the DCs and intracellular processing for
subsequent cross-presentation to the MHC class I pathway.
To confirm that cross-presentation was required for CD8þ
activation by DC presentation of the long peptide, we first
showed that proGLC did not induce CD8þ activation
without the aid of antigen-presenting cells. BMLF-1 epitope–-
specific CD8þ T cells were able to auto-present the 9-amino-
acid HLA-A2 peptide but not the 39-amino-acid-long peptide
(Supplementary Figure S1c online). Fixed or unfixed DCs were
pulsed for 24 hours with or without EBV peptide or proGLC,
washed, and assayed for capacity to present the EBV epitope
to CD8þ lymphocytes. In addition, to determine the role of
intracellular processing, unfixed DCs were pulsed for
24hours, washed, and then fixed before use in the same
assay. The superiority of LCs over DDCs in presenting the
9-amino-acid EBV epitope was unaffected by fixation before
or after peptide pulsing, reflecting surface loading of the short
peptide and lack of the need for intracellular processing
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Figure 5. Blockade of CD70 signaling inhibits CD8þ activation in
Langerhans cells but not dermal dendritic cells. IFN-g ELISpot assay of EBV-
specific T cells stimulated with EBV peptide–pulsed LCs (LC, gray bars) or
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(Figure 6a), as well as showing that the light fixation used here
did not significantly impair DC/T-cell interaction.
In contrast to the 9-amino-acid EBV epitope (Figure 6a),
presentation of the long peptide by skin DCs was completely
abrogated by fixation, confirming that antigen uptake from
the extracellular compartment is required for initiation of
CD8þ immune responses targeting the EBV epitope within
the long peptide (Figure 6b); thus, confirming that the
presentation of the EBV epitope within proGLC requires
cross-presentation (Groothuis and Neefjes, 2005).
Importantly, without fixation, LCs were significantly
superior (P¼0.0045) compared with DDCs in capacity to
cross-present the long peptide to CD8þ T lymphocytes
(Figure 6b). Yet, despite 24 hours exposure to proGLC and
washing to remove the residual long peptide, unfixed cells
were superior to cells fixed just before activation of CD8þ
lymphocytes; therefore, suggesting that DC surface expres-
sion of EBV peptide–loaded MHC class I is ongoing after
24 hours (Figure 6b). This confirms that presentation of the
HLA-A2-restricted EBV epitope from 39-amino-acid proGLC
is dependent upon a functional intracellular MHC class I
pathway. Similar to the results with the short EBV peptide,
addition of anti-CD70 antibody significantly reduced cross-
presentation of the longer proGLC peptide by LCs (Po0.05)
but not by DDCs, demonstrating that CD70 signaling is also
important for cross-presented epitopes by LCs but not by
DDCs (Figure 6c).
DISCUSSION
As subsets of skin DCs reside in separate cutaneous
compartments, they are exposed to unique microenviron-
ments and diverse antigens. In vivo, human LCs are able to
recognize viral RNA by intracellular expression of TLR3,
TLR7, and TLR8, which strongly induce maturation and IL-6
production (Suzuki et al., 2000; Flacher et al., 2006; Fahey
et al., 2009). These data suggest that LCs have an important
need for efficient HLA class I antigen presentation, which
may suggest an evolutionary adaptation to counter epidermal
virus infections. Indeed, LCs are infected early with infections
such as human papilloma virus, herpes simplex, and HIV and
have been found to have an essential role in host defense
against these viruses (Cunningham et al., 2008). Thus, it is
possible that the need for strong CD8þ epidermal immunity
has driven a requirement for LC cellular machinery to deliver
a strong signal to CD8þ lymphocytes.
CD70 is a member of the TNF superfamily and the ligand
for the co-stimulatory receptor CD27 (Bowman et al., 1994).
CD27 signaling results in the activation of nuclear factor-kB
and c-Jun N-terminal kinase, which leads to enhanced
proliferation and survival of T cells, as well as promoting
effector function and T-cell accumulation at effector sites
(Agematsu et al., 1994; Kobata et al., 1994; Hintzen et al.,
1995; Arens et al., 2001; Hendriks et al., 2003; Rowley and
Al-Shamkhani, 2004; Taraban et al., 2004). CD27 is also
important in delivering signals to CD8þ T cells that
determine the size of the CD8þ memory T-cell pool and
improve the capacity of these memory cells to undergo
secondary expansion (Hendriks et al., 2005). Studies in mice
have suggested that CD70 is required for generation of long-
term immunity (Hendriks et al., 2000) and seems to be
particularly important for the generation of CD8þ cytotoxic
responses to viruses (Rowley and Al-Shamkhani, 2004;
Taraban et al., 2006; Ballesteros-Tato et al., 2010), and it
has recently been shown to be important in the induction of
contact hypersensitivity in mice (Kawamura et al., 2011).
Here, we have shown that primary human LCs were more
highly activated than their DDC counterparts as measured by
the expression of co-stimulatory molecules, and this differ-
ence was accentuated after maturation with TNF-a, but that
up-regulation of expression of CD70 was restricted to LCs.
Furthermore, our data demonstrate that LCs are superior to
DDCs in presentation and cross-presentation of antigens
to CD8þ T cells, resulting in a more robust response with
high levels of IFN-g, dependent on CD70/CD27 signaling.
A recent independent concurrent study (van der Aar et al.,
2011) reported that in vitro poly I:C and influenza virus are
also able to upregulate CD70 expression on LCs with
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Figure 6. Langerhans cells more efficiently cross-present to CD8þ
lymphocytes than dermal dendritic cells and use CD70 co-stimulation.
(a, b) IFN-g ELISpot assay of EBV-specific CD8þ cells stimulated by LCs or
DDCs pulsed with or without short EBV peptide (EBV) (a) or 39-amino-acid
(proGLC) peptide (b). Dendritic cells were unfixed and pulsed (light gray),
fixed then pulsed (dark gray), or pulsed before fixation (black). n¼ 3 independent
experiments in triplicate; data presented are from one representative
experiment, mean±SEM. (c). IFN-g ELISpot assay of EBV-specific CD8þ
cells stimulated by LCs or DDCs pulsed with proGLC with (black) or without
(gray) CD70 blockade (a-CD70). n¼ 5, mean±SEM. DDC, dermal dendritic
cell; EBV, Epstein–Barr virus; LC, Langerhans cell; NS, nonsignificant.
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concomitant increased staphylococcal superantigen–induced
proliferation of naive CD8þ lymphocytes. We examined the
skin DCs for TNF-a maturation–induced cytokines, and
although LCs and DDCs showed similar levels of IL-1b, IL-
4, IL-10, IL-12p70, TNF-a, and IL-27 release, DDCs showed
upregulation of expression of IL-6 and IL-8. However, despite
these differences, LCs were significantly better able to
activate memory CD8þ T cells, which could be attenuated
by blockade of CD70–CD27 signaling. Data presented here
suggest that DDCs do not use CD70 for optimal activation of
CD8þ lymphocytes, but through the use of other co-
stimulatory molecules such as CD86 (Figure 5) they remain
functional albeit at a lesser level.
The important role of LCs in skin immunity is further
emphasized by their efficiency in cross-presentation of antigens
such as those encountered by epidermal infection or carcino-
genesis. It is interesting to speculate on the fine balance
achieved between the need for a sensitive cutaneous system of
immunity providing effective host defense against dangerous
pathogens counterbalanced by the requirement to avoid
unnecessary damaging immune responses provoked by the
continuous engagement of the skin with foreign antigens. The
potency of CD8þ responses licensed by LC CD70 expression
provides evidence for a strong requirement for epidermal
immunity against MHC I antigens such as viruses and possibly
precancerous lesions, whereas the inability of DDCs to deliver
CD27 signals may suggest an advantage in limiting potentially
harmful CD8þ responses in the dermal compartment.
The importance of skin DCs in conferring systemic
immunity is highlighted by work showing that intra-dermal
influenza vaccination required 20% of the dose of the
conventional intra-muscular delivery to achieve the same
protection (Kenney et al., 2004). In addition, a recent clinical
trial demonstrated that transcutaneous influenza vaccination
induced significantly superior CD8þ effector T cells as
compared with intra-muscular delivery (Combadiere et al.,
2010). LCs act as the outermost guard of the cutaneous
immune system and are likely to induce the first reactions
against pathogens encountered via the skin and against
transcutaneous vaccines. On the basis of the greater ability of
LCs to activate CD8þ cells, LCs may represent an attractive
proposition for targeted immunological intervention, e.g., by
concomitant manipulation of CD70–CD27 signaling. Topical
or microneedle vaccine delivery would be expected to
preferentially target LCs, thereby boosting a strong CD8þ
memory immune response, whereas deeper injection into the
dermis or subcutis may achieve a lesser effect. Furthermore,
our data demonstrate that LCs can cross-present antigens to
induce a more robust cytotoxic T-cell response with high
levels of IFN-g, which is critical to host defense against
viruses, microbes, and cancer (Boehm et al., 1997). This
finding suggests that vaccine technologies considered for
transcutaneous vaccination need not be confined to retroviral
vectors and DNA vaccines, but that peptide or protein
vaccines, which are technically simpler and considered to be
safer, may be similarly effective. Enhancing CD70 signaling
in a vaccine setting has been shown to break CD8þ
tolerance (Suzuki et al., 2000; Keller et al., 2008, 2009),
and this approach would provide an important advantage for
cutaneous delivery of CD8þ vaccines, including those that
target therapeutic immune responses against self-proteins
present in epidermal cancers.
In conclusion, human LCs are more efficient than DDCs in
activating CD8þ T cells as a result of higher expression of CD70
by LCs. Thus, CD70/CD27–mediated activation of CD8þ T cells
by LCs may represent an important mechanism for enhancing
immune responses against viral skin infections and skin cancers.
MATERIALS AND METHODS
Human skin migratory DCs
The study was conducted according to the Declaration of Helsinki
Principles. HLA-A2 skin specimens were obtained from healthy
individuals, after acquiring their written informed consent as approved
by the University of Southampton Ethics Committee. Following dispase
(2Uml1, Gibco, Paisley, UK) enzymatic digestion, epidermal sheets
and dermal fragments were separately incubated in culture medium
(RPMI with 100 IUml1 penicillin and 100mgml1 streptomycin) with
10% fetal calf serum at 371C, 5% CO2. Migratory DCs were collected
at 48hours, and assayed for yield and cell viability after density
gradient centrifugation (1:4.2 Optiprep, Axis-Shield, UK). DC matura-
tion was tested with TNF-a, CD40L, and polyI:C. DC activation was
best delivered by TNF-a (25ngml1, Peprotech, London, UK; Figure 1b)
as previously reported (Berthier-Vergnes et al., 2005). Briefly, 5 104
DCs were incubated in 200-ml culture medium supplemented with
TNF-a for 24hours or 5 days (IL-15, IL-27).
Supernatants from untreated or TNF-a-matured skin DCs
(7.5 104 cells per 100ml) were assayed for IL-1b, IL-6, IL-8, IL-
10, and TNF-a with a multi-cytokine bead array (Luminex,
Invitrogen, Paisley, UK) and for IL-12p70 (R&D Systems, Abingdon,
UK) after 24 hours and IL-15 and IL-27 by ELISA (eBioscience,
Hatfield, UK) after 5 days.
For pulsing, DCs were incubated with 100mMml1 HLA A2
epitope EBV peptide (BMLF-1 280-8: GLCTLVAML; Cambridge
Peptides, Cambridge, UK) for 18 hours with TNF-a after 2 hours and
were washed thoroughly before coculture with T cells. For cross-
presentation experiments, DCs were pulsed with proGLC (10 mM) for
24 hours and supplemented with TNF-a after 6 hours (proGLC:
FNNFTVSFWLRVPKVSASHLEGLCTLVAML; C-terminus BMLF-1
epitope; Peptide Protein Research, Fareham, UK). Purity was
confirmed by HPLC 499% purity and single peak mass spectro-
metry. For fixation, 0.05% glutharaldehyde was used as described
previously (Pickard et al., 2007).
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